Tuesday, February 3

Healthcare

HUTCHMED pulls regulatory submission for Takeda-partnered cancer drug in China

08/31/20241 Min Read

cancer China drug HUTCHMED pulls regulatory submission Takedapartnered

Previous ArticleMediciNova gains after patent win for long COVID therapy

Next Article Alnylam falls after full data for heart drug that can rival Pfizer’s